2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 12, 2019

2:30PM-4:00PM: Abstract Number: 2771

A Phase I, Randomized, Double-blind, Placebo-controlled, Single Center, Single-dose Escalation to Investigate the Safety, Tolerability, and Pharmacodynamics of Subcutaneously Administered DEN-181 in Adult Patients with ACPA+ Rheumatoid Arthritis on Stable Methotrexate

5T092: RA – Treatments IV: Novel Therapy & Predicting Response (2768–2773)

2:30PM-4:00PM: Abstract Number: 2778

Alcohol Consumption as a Predictor of the Progression of Spinal Structural Damage in Axial Spondyloarthritis: Data from the Catholic Axial Spondyloarthritis COhort (CASCO)

5T094: Spondyloarthritis Including Psoriatic Arthritis – Clinical V: Axial Spondyloarthritis Clinical Studies (2774–2779)

2:30PM-4:00PM: Abstract Number: 2784

Alterations in Inflammatory, TNF-Superfamily, and IFN-Associated Chemokines Precede Clinical Changes in SLEDAI After Methylprednisolone Treatment of SLE Patients

5T093: SLE – Clinical V: Emerging Knowledge of Current Treatments (2780–2785)

2:30PM-4:00PM: Abstract Number: 2744

Altered Expression of CD52 Facilitates Adhesion of Circulating CD14+ Monocytes in Systemic Sclerosis

5T095: Systemic Sclerosis & Related Disorder – Basic Science (2744–2749)

2:30PM-4:00PM: Abstract Number: 2765

Assessing the Impact of Digital Health Coaching on Quality Adjusted Life Years, Symptom Severity and Disease Activity in Patients with Rheumatoid Arthritis

5T091: Patient Outcomes, Preferences, & Attitudes II: Patient Preferences, Beliefs, & Experiences (2762–2767)

2:30PM-4:00PM: Abstract Number: 2755

Assessing the Sensitivity to Change of the OMERACT Ultrasound Structural Gout Lesions During Urate-Lowering Therapy

5T089: Imaging of Rheumatic Diseases II (2750–2755)

2:30PM-4:00PM: Abstract Number: 2754

AxSpA Patients with Symptom Onset < 30 Years Have More Structural Lesions on MRI of the Sacroiliac Joints When Fulfilling the Modified New York Criteria

5T089: Imaging of Rheumatic Diseases II (2750–2755)

2:30PM-4:00PM: Abstract Number: 2785

Cancer Risk in a Large Inception SLE Cohort: Effects of Age, Smoking, and Medications

5T093: SLE – Clinical V: Emerging Knowledge of Current Treatments (2780–2785)

2:30PM-4:00PM: Abstract Number: 2761

Cartilage Thickness Modification with Sprifermin in Knee Osteoarthritis Patients Translates into Symptomatic Improvement over Placebo in Patients at Risk of Further Structural and Symptomatic Progression: Post-Hoc Analysis of a Phase II Trial

5T090: Osteoarthritis – Clinical II: Novel Therapies (2756–2761)

2:30PM-4:00PM: Abstract Number: 2768

Changes in B Cell Profile as a Marker of Clinical Remission to TNF Inhibitors in Patients with Rheumatoid Arthritis

5T092: RA – Treatments IV: Novel Therapy & Predicting Response (2768–2773)

2:30PM-4:00PM: Abstract Number: 2743

Characterizing the Epigenomic Landscape of Psoriasis Patients Destined to Develop Psoriatic Arthritis

5T088: Genetics, Genomics & Proteomics (2738–2743)

2:30PM-4:00PM: Abstract Number: 2772

Clinical and Biological Changes in Rheumatoid Arthritis Patients Exposed to an Anti-inflammatory Diet

5T092: RA – Treatments IV: Novel Therapy & Predicting Response (2768–2773)

2:30PM-4:00PM: Abstract Number: 2757

Clinical Effectiveness of Ultrasound-guided Intra-articular Corticosteroid and Local Anaesthetic Injections for Hip Osteoarthritis: A Randomised Controlled Trial (HIT)

5T090: Osteoarthritis – Clinical II: Novel Therapies (2756–2761)

2:30PM-4:00PM: Abstract Number: 2774

Cluster-based Spondyloarthritis Phenotypes Defined at Baseline Are Predictive of Different Severity Outcomes at 5-Year in the DESIR Cohort

5T094: Spondyloarthritis Including Psoriatic Arthritis – Clinical V: Axial Spondyloarthritis Clinical Studies (2774–2779)

2:30PM-4:00PM: Abstract Number: 2782

Comparative Risks of Cardiovascular Disease Among SLE Patients Receiving Immunosuppressive Medications

5T093: SLE – Clinical V: Emerging Knowledge of Current Treatments (2780–2785)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].